Copovidone Market

By Application;

Pharmaceuticals, Cosmetics, Food Industry and Others

By Formulation;

Tablets, Capsules, Powders and Ointments

By End-User;

Healthcare, Personal Care, Food & Beverage and Industrial Applications

By Product;

Copovidone K-30, Copovidone K-60 and Copovidone K-90

By Distribution Channel;

Direct Sales, Online Retailers, Distributors & Wholesalers and Pharmaceutical & Cosmetic Suppliers

By Geography;

North America, Europe, Asia Pacific, Middle East & Africa and Latin America - Report Timeline (2021 - 2031)
Report ID: Rn364957723 Published Date: September, 2025 Updated Date: October, 2025

Copovidone Market Overview

Copovidone Market (USD Million)

Copovidone Market was valued at USD 282.94 million in the year 2024. The size of this market is expected to increase to USD 398.13 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 5.0%.


Copovidone Market

*Market size in USD million

CAGR 5.0 %


Study Period2025 - 2031
Base Year2024
CAGR (%)5.0 %
Market Size (2024)USD 282.94 Million
Market Size (2031)USD 398.13 Million
Market ConcentrationMedium
Report Pages321
282.94
2024
398.13
2031

Major Players

  • Ashland
  • BASF
  • JH Nanhang
  • BOC Sciences
  • Resonac Corporation
  • JRS Pharma
  • Clinivex
  • Glentham Life Sciences
  • Markan Global Enterprises
  • VIVAN Life Sciences
  • BOAI NKY MEDICAL HOLDINGS LTD
  • Star-Tech & JRS Specialty Products Co., Ltd
  • GUANGDONG YUMAY CHEMICAL CO., LTD
  • Hangzhou Sunflower Technology Development Co., Ltd
  • SHANGHAI YUKING WATER SOLUBLE MATERIAL TECH CO., LTD
  • Shanghai Dexiang Medicine Tech Co., Ltd

Market Concentration

Consolidated - Market dominated by 1 - 5 major players

Copovidone Market

Fragmented - Highly competitive market without dominant players


The Copovidone Market is gaining momentum as this excipient becomes vital in pharmaceutical innovation. Praised for its high solubility, binding efficiency, and film-forming properties, copovidone significantly enhances drug performance. Currently, nearly 45% of oral solid dosage forms rely on copovidone to improve drug stability and patient outcomes.

Industry Overview
With the rising demand for innovative drug delivery methods, copovidone adoption is accelerating. Around 40% of pharmaceutical producers integrate it into controlled-release and taste-masking systems. Its versatile role in nutraceuticals and dietary supplements also boosts its acceptance, establishing it as a key component across therapeutic solutions.

Factors Driving Demand
A shift toward patient-centric healthcare formulations is one of the strongest growth drivers. Nearly 38% of newly approved oral medications feature copovidone to enhance dissolution and hardness of tablets. Its adaptability ensures superior performance, making it a top choice for complex and advanced drug formulations.

Innovations and Developments
Rapid progress in formulation science and delivery technologies strengthens copovidone’s role in modern pharmaceuticals. Today, almost 50% of its usage comes from applications like hot-melt extrusion and solid dispersions. These approaches boost solubility for difficult drugs, ensuring higher therapeutic efficiency and better patient results.

Future Market Insights
The future of the Copovidone Market looks promising, with over 55% of pharmaceutical companies expected to expand its role in drug innovation. Rising investment in R&D, formulation improvements, and next-generation therapies will continue to reinforce copovidone’s dominance in shaping pharmaceutical advancements.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Application
    2. Market Snapshot, By Formulation
    3. Market Snapshot, By End-User
    4. Market Snapshot, By Product
    5. Market Snapshot, By Distribution Channel
    6. Market Snapshot, By Region
  4. Copovidone Market Dynamics
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Increasing demand for effective drug delivery systems
        2. Growth in pharmaceutical and healthcare sectors
        3. Rising prevalence of chronic diseases
        4. Regulatory approval for use in drug formulations
      2. Restraints
        1. High manufacturing costs of copovidone
        2. Limited availability of raw materials
        3. Stringent regulatory requirements
      3. Opportunities
        1. Expansion in emerging markets
        2. Growing applications in the cosmetic industry
        3. Development of new drug formulations
        4. Technological advancements in copovidone production
      4. PEST Analysis
        1. Political Analysis
        2. Economic Analysis
        3. Social Analysis
        4. Technological Analysis
      5. Porter's Analysis
        1. Bargaining Power of Suppliers
        2. Bargaining Power of Buyers
        3. Threat of Substitutes
        4. Threat of New Entrants
        5. Competitive Rivalry
  5. Market Segmentation
    1. Copovidone Market, By Application, 2021 - 2031 (USD Million)
      1. Pharmaceuticals
      2. Cosmetics
      3. Food Industry
      4. Others
    2. Copovidone Market, By Formulation, 2021 - 2031 (USD Million)
      1. Tablets
      2. Capsules
      3. Powders
      4. Ointments
    3. Copovidone Market, By End-User, 2021 - 2031 (USD Million)
      1. Healthcare
      2. Personal Care
      3. Food & Beverage
      4. Industrial Applications
    4. Copovidone Market, By Product, 2021 - 2031 (USD Million)
      1. Copovidone K-30
      2. Copovidone K-60
      3. Copovidone K-90
    5. Copovidone Market, By Distribution Channel, 2021 - 2031 (USD Million)
      1. Direct Sales
      2. Online Retailers
      3. Distributors & Wholesalers
      4. Pharmaceutical & Cosmetic Suppliers
    6. Copovidone Market, By Geography, 2021 - 2031 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Rest of Europe
        2. Benelux
        3. Nordic
        4. Spain
        5. Italy
        6. France
        7. United Kingdom
        8. Germany
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia & New Zealand
        5. South Korea
        6. ASEAN (Association of South East Asian Countries)
        7. Rest of Asia Pacific
      4. Middle East & Africa
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  6. Competitive Landscape
    1. Company Profiles
      1. Ashland
      2. BASF
      3. JH Nanhang
      4. BOC Sciences
      5. Resonac Corporation
      6. JRS Pharma
      7. Clinivex
      8. Glentham Life Sciences
      9. Markan Global Enterprises
      10. VIVAN Life Sciences
      11. BOAI NKY MEDICAL HOLDINGS LTD
      12. Star-Tech & JRS Specialty Products Co., Ltd
      13. GUANGDONG YUMAY CHEMICAL CO., LTD
      14. Hangzhou Sunflower Technology Development Co., Ltd
      15. SHANGHAI YUKING WATER SOLUBLE MATERIAL TECH CO., LTD
  7. Analyst Views
  8. Future Outlook of the Market